A major analysis of nearly 90,000 patients reveals that people who shed substantial weight using popular GLP-1 medications slashed their risk of serious obesity-related diseases by up to 69 percent, while those who gained weight faced significantly worse health prospects.
The findings, presented at the European Congress on Obesity, analyzed real-world treatment outcomes from January 2021 through June 2025 using data from a massive US electronic health records database. Researchers tracked patients starting semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), or liraglutide (Saxenda) to see how weight changes in that critical first year affected their likelihood of developing osteoarthritis, chronic kidney disease, obstructive sleep apnea, and heart failure.
The scale of the cohort was substantial: 89,718 patients with an average age of 57.5 and BMI of 34.7, with roughly six in ten having type 2 diabetes. Three-quarters started on semaglutide drugs, while smaller portions began tirzepatide or liraglutide treatments.
Weight loss emerged as a powerful protective factor. Among patients who achieved at least a 15 percent BMI reduction, osteoarthritis risk dropped 37 percent compared to minimal weight loss. Chronic kidney disease risk fell 30 percent. Obstructive sleep apnea plummeted 69 percent, the single most dramatic benefit. Heart failure risk dropped 32 percent, though this finding lacked statistical significance.
The breakdown of actual weight outcomes across the patient population tells a crucial story about both the drugs' effectiveness and their limitations. About 27 percent of patients lost less than 5 percent of their BMI, while 22.4 percent achieved the 5 to 10 percent range. Another 14.1 percent hit between 10 and 15 percent, and only 15.8 percent reached the threshold of at least 15 percent reduction. Notably, one in five patients actually gained weight despite starting treatment.
The weight gain cohort presented a troubling inverse picture. Those who put on pounds faced a 10 percent higher osteoarthritis risk, a 14 percent elevation in chronic kidney disease danger, a 22 percent increase in sleep apnea risk, and a startling 69 percent spike in heart failure risk compared to minimal weight loss patients. The sleep apnea and heart failure increases reached statistical significance, suggesting real danger rather than random variation.
A striking detail underscores the challenge of medication adherence: approximately half of all patients discontinued their GLP-1 treatment within one year. This dropout rate did not invalidate the research, as investigators tracked all participants based on their actual weight outcomes regardless of continuous drug use, but it highlights why real-world results often diverge sharply from clinical trial promise.
Researchers emphasized that sustained weight loss, not merely starting medication, drove the health benefits. In a population where treatment abandonment ran at 50 percent, the data showed that weight loss was the operative factor for improved outcomes while failure to lose weight correlated with deteriorating health prospects.
Author Jessica Williams: "The research cuts through the hype and gets at what actually matters: these drugs work when they work, but only sustained weight loss translates to real disease prevention."
Comments